Semaglutide Shows Potential to Slow Biological Aging in First Clinical Study
A new study has found that semaglutide—the active ingredient in Ozempic and Wegovy—may have effects beyond weight loss and metabolic health. Researchers discovered that the drug slowed biological aging markers in adults with HIV, marking the first clinical evidence that semaglutide could influence human aging processes.
The findings offer an intriguing possibility that these widely used GLP-1 receptor agonists might have anti-aging properties. However, scientists emphasize that larger, longer-term studies are needed before any conclusions can be drawn about the medication's potential to help people age more slowly.